MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.
Dasatinib (BMS-354825) is a FDA-approved multitargeted kinase inhibitor of BCR/ABL and Src kinases. It is now used in the treatment of chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapies, including imatinib. Here we report a novel effect of dasatinib on inducing the...
Main Authors: | Yanfen Fang, Like Zhong, Meihua Lin, Xinglu Zhou, Hui Jing, Meidan Ying, Peihua Luo, Bo Yang, Qiaojun He |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3692534?pdf=render |
Similar Items
-
DASATINIB IN CHRONIC MYELOID LEUKEMIA
by: Mojca Modic
Published: (2008-04-01) -
Use of dasatinib in chronic myeloid leukemia therapy
by: O. Yu. Vinogradova, et al.
Published: (2008-12-01) -
Dasatinib in chronic myeloid leukemia: a review
by: Dolly G Aguilera, et al.
Published: (2009-03-01) -
Systematic review of dasatinib in chronic myeloid leukemia
by: Breccia M, et al.
Published: (2013-03-01) -
The role of dasatinib in the management of chronic myeloid leukemia
by: Chen R, et al.
Published: (2015-02-01)